C3.ai (NYSE:AI) recently reported strong year-over-year revenue growth for the third quarter and first nine months of fiscal 2025, but with a wider net loss than the previous year. In the last week, ...

This estate-style family car is tuned for comfort, with the option of extra folding chairs to seat up to seven – though that ...

India on Monday proposed a multi-nation alliance for technical collaboration, partnerships, and cooperation between private ...

C3.ai, Inc. (AI) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Manohar Lal, Union Minister for Housing and Urban Affairs, on Monday announced the Cities Coalition for Circularity (C-3), a ...

C3.ai (NYSE:AI – Free Report) had its price objective lowered by DA Davidson from $40.00 to $25.00 in a research report sent to investors on Thursday,Benzinga reports. The brokerage currently has a ...

Needham & Company LLC reiterated their hold rating on shares of C3.ai (NYSE:AI – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. Other research analysts have ...

Tmall Magic Screen C3 Air projector debuts with 1080P resolution, a built-in clock, a 360° adjustable stand, and an SSD2381 chip.

Feb. 27 at approximately 6:35 p.m., members of the Springfield Police C3 Units seized a loaded firearm and arrested ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Shares of C3.ai Inc. AI slipped 1.80% to $23.45 Friday, on what proved to be an all-around positive trading session for the ...

We recently compiled a list of the Why These 15 AI Stocks Are Plunging So Far in 2025. In this article, we are going to take ...